Engineering parvovirus-like particles for the induction of B-cell, CD4+ and CTL responses

Rueda, Paloma; Martı́nez-Torrecuadrada, Jorge L.; Sarraseca, Javier; Sedlik, Christine; Barrio, Manuel del; Hurtado, Alicia; Leclerc, Claude; Casal, J. Ignacio

doi:10.1016/s0264-410x(99)00202-9

Cited by 38 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is a laborious, patient-restricted and expensive process. The second method to develop effective tumor vaccines is to construct exogenous antigen vaccines such as live attenuated virus 22 or bacteria, 23 peptide, 24 modified peptide, 25 liposome 26 or ISCOMs, 27 chimeric virus particles, 28 particle protein 29 and naked DNA. 30 These vaccines must be presented by professional APC in vivo to elicit CTL responses against tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Phage display particles expressing tumor‐specific antigens induce preventive and therapeutic anti‐tumor immunity in murine p815 model

Wan

Bian

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

The efficacy of phage display particles expressing tumor antigen P1A35-43 in inducing protective and therapeutic anti-tumor immune responses were studied. A protective immune response against a lethal progressive P815 mastocytoma tumor cell challenge was established after subcutaneous injection of phage display particles. Furthermore, the vaccine suppressed growth of pre-existing tumors. Immunization with the hybrid phage particles elicited P1A 35-43 specific CTL responses and a Th1-dominated immune response with phage particle-specific secretion of IFN-␥ but not IL-4. Our results indicate that phage display particles might be a useful vaccine form for tumor-associated antigen epitopes in tumor immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Phage display particles expressing tumor‐specific antigens induce preventive and therapeutic anti‐tumor immunity in murine p815 model

Wan

Bian

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Purification of PPV-VLPs was carried out as previously described (Casal, 1999;Rueda et al, 1999). Briefly, infected Sf9 cells were lysed by hypotonic shock with 25 mM bicarbonate solution at 4 uC.…”

Section: Methodsmentioning

confidence: 99%

Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles

Rueda¹,

Morón

Sarraseca³

et al. 2004

Journal of General Virology

View full text Add to dashboard Cite

We have previously developed an antigen-delivery system based on hybrid recombinant porcine parvovirus-like particles (PPV-VLPs) formed by the self-assembly of the VP2 protein of PPV carrying a foreign epitope at its N terminus. In this study, different constructs were made containing a CD8 + T-cell epitope of chicken ovalbumin (OVA) to analyse the influence of the sequence inserted into VP2 on the correct processing of VLPs by antigen-presenting cells. We analysed the presentation of the OVA epitope inserted without flanking sequences or with either different natural flanking sequences or with the natural flanking sequences of a CD8 + T-cell epitope from the lymphocytic choriomeningitis virus nucleoprotein, and as a dimer with or without linker sequences. All constructs were studied in terms of level of expression, assembly of VLPs and ability to deliver the inserted epitope into the MHC I pathway. The presentation of the OVA epitope was considerably improved by insertion of short natural flanking sequences, which indicated the relevance of the flanking sequences on the processing of PPV-VLPs. Only PPV-VLPs carrying two copies of the OVA epitope linked by two glycines were able to be properly processed, suggesting that the introduction of flexible residues between the two consecutive OVA epitopes may be necessary for the correct presentation of these dimers by PPV-VLPs. These results provide information to improve the insertion of epitopes into PPV-VLPs to facilitate their processing and presentation by MHC class I molecules.

show abstract

“…De esta forma, en cada VLP hay varias copias del epítopo, generándose una respuesta inmune frente a la cápsida y frente al epítopo. Existen numerosos trabajos que describen su capacidad protectora (Antonis et al, 2006;Rueda et al, 1999).…”

Section: Las Vacunas En Veterinariaunclassified

La biotecnología en sanidad animal

García

Casares

Moran

et al. 2014

Arbor

View full text Add to dashboard Cite

RESUMEN: El crecimiento de la población mundial en los próxi-mos años, provocará un incremento en la demanda de alimentos. Como consecuencia, el número de animales de producción sufrirá un aumento importante y la Sanidad Animal constituirá un elemento crítico a la hora de tratar y prevenir las enfermedades, garantizando el abastecimiento y la seguridad. La biotecnología contribuye de múltiples formas al desarrollo de la Sanidad Animal. Fundamentalmente, aporta herramientas que ayudan al control y erradicación de las enfermedades. El desarrollo de la ingeniería genética en las últimas décadas ha favorecido el avance de la industria biotecnológica aplicada a la sanidad humana y animal. Existen un gran número de ensayos de diagnóstico basados en desarrollos biotecnológicos, así mismo, cada vez hay más vacunas recombinantes contra enfermedades animales. La prevención y control eficientes de las enfermedades dependerán de mecanismos de detección temprana, que faciliten la toma de decisiones y una respuesta rápida. PALABRAS CLAVE:Vacunación; VLPs; diagnóstico; inmunoensayos; DIVA; ensayos múltiples; ensayos de campo; PCR.ABSTRACT: The growth of the world population in forthcoming years will cause an increase in the demand of food. As a result, the number of working animals is set to rise significantly and Animal Health will become a vital issue when it comes to treating and preventing diseases, and guaranteeing and uninterrupted and safe food supply. Biotechnology contributes to the development of Animal Health in many ways. First and foremost, it provides tools that help control and eradicate diseases. The progress of genetic engineering in recent decades has underpinned the development of the biotechnology industry applied to human and animal health. There are a large number of diagnostic tests based on biotechnological developments, and there is also an increase in the use of recombinant vaccines against animal diseases. An effective prevention and control of diseases will depend on early detection mechanisms that facilitate decisionmaking and enable a rapid response. KEYWORDS:Vaccination; VLPs; diagnostic; immunoassays; DIVA; multiplex assays; field tests; PCR.

show abstract

Engineering parvovirus-like particles for the induction of B-cell, CD4+ and CTL responses

Cited by 38 publications

References 20 publications

Phage display particles expressing tumor‐specific antigens induce preventive and therapeutic anti‐tumor immunity in murine p815 model

Phage display particles expressing tumor‐specific antigens induce preventive and therapeutic anti‐tumor immunity in murine p815 model

Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles

La biotecnología en sanidad animal

Contact Info

Product

Resources

About